You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immunoconjugates

Showing 101 - 113 of 113
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer Trial in Seattle (Laboratory Biomarker Analysis,

Completed
  • HER2/Neu Positive
  • +4 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 19, 2017

Breast Cancer Trial in United States (MM-302 Monotherapy, MM-302 in combination with trastuzumab, MM-302 in combination with

Unknown status
  • Breast Cancer
  • MM-302 Monotherapy
  • +3 more
  • San Francisco, California
  • +4 more
Jan 4, 2017

Peripheral T-Cell Lymphoma Trial in Tampa (Brentuximab vedotin)

Terminated
Has Results
  • Peripheral T-Cell Lymphoma
  • Brentuximab vedotin
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Nov 22, 2016

Recurrent Adult Hodgkin Lymphoma Trial in New York (Brentuximab Vedotin, Laboratory Biomarker Analysis, Temsirolimus)

Completed
  • Recurrent Adult Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +2 more
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Nov 6, 2015

Renal Cell Carcinoma Trial in Worldwide (ABR-217620/naptumomab estafenatox, IFN-alpha)

Completed
  • Renal Cell Carcinoma
  • Pleven, Bulgaria
  • +50 more
Jun 30, 2015

Leukemia, Lymphoma Trial in Los Angeles, Washington, St. Paul (B43-genistein immunoconjugate)

Unknown status
  • Leukemia
  • Lymphoma
  • B43-genistein immunoconjugate
  • Los Angeles, California
  • +2 more
Sep 19, 2013

GVHD Trial in Seattle (brentuximab vedotin, laboratory biomarker analysis, pharmacological study)

Withdrawn
  • Graft Versus Host Disease
  • brentuximab vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutchinson Cancer Research Center/University of Washington
Jun 25, 2013

Lymphoma Trial (brentuximab vedotin)

Withdrawn
  • Lymphoma
  • brentuximab vedotin
  • (no location specified)
Jul 24, 2013

Ovarian Tumors Trial in United States (SGN-15 (cBR96-Doxorubicin Immunoconjugate), Gemzar (Gemcitabine))

Terminated
  • Ovarian Neoplasms
  • SGN-15 (cBR96-Doxorubicin Immunoconjugate)
  • Gemzar (Gemcitabine)
  • Tucson, Arizona
  • +5 more
Oct 21, 2011

Breast Cancer Trial in Birmingham (cBR96-doxorubicin immunoconjugate, docetaxel)

Terminated
  • Breast Cancer
  • Birmingham, Alabama
    University of Alabama at Birmingham Comprehensive Cancer Center
Oct 21, 2011

Prostatic Tumors Trial in United States (SGN-15 (cBR96-doxorubicin immunoconjugate), Taxotere (docetaxel))

Completed
  • Prostatic Neoplasms
  • SGN-15 (cBR96-doxorubicin immunoconjugate)
  • Taxotere (docetaxel)
  • Tucson, Arizona
  • +10 more
Oct 21, 2011

Leukemia, Lymphoma Trial run by the (BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy)

Completed
  • Leukemia
  • Lymphoma
  • BL22 immunotoxin
  • +2 more
  • Bethesda, Maryland
    Warren Grant Magnuson Clinical Center - NCI Clinical Trials Refe
Jun 17, 2010

Leukemia, Lymphoma Trial run by the (BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy)

Suspended
  • Leukemia
  • Lymphoma
  • BL22 immunotoxin
  • +3 more
  • Bethesda, Maryland
    Warren Grant Magnuson Clinical Center - NCI Clinical Trials Refe
Dec 21, 2007